PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Myoinositol

Drugs in development · updated 5 November 2026

Myoinositol: clinical trials and development status

NLM verified identityNot approved in the USNo EMA authorisationEstimated launch Jan 2028 – Nov 2028 (Phuturdex estimate)

As of 5 November 2026 Myoinositol is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 3 diseases. The most advanced phase is III.

3Active trials
IIIMost advanced phase
3Diseases studied

Summary updated every week · data as of 5 November 2026. In Phuturdex you can follow Myoinositol and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Male infertilityIII1NCT07915388
VaricoceleIII1NCT07915388
Polycystic Ovary SyndromeI1NCT07459595

Everything on Myoinositol

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 5 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch